RET and non-small cell lung carcinoma: In 47 patients with RET fusion-positive NSCLC, ORR was 69.2% (95% CI: 48.2–85.7).52 Beyond clinical trials, in a real-world retrospective study, selpercatinib was demonstrated to achieve an ORR of 68% and a disease control rate of 92% in 50 patients with RET fusion-positive NSCLC.